


## **Technology Advisory Committee D Interests Register**

Topic: Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung

cancer after platinum-based chemotherapy [ID3836]

**Publication Date: 14 December 2022** 

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Ivan Koychev	Committee member	Indirect financial	Dr Koychev has a collaboration with Johnson and Johnson in an unrelated area (Alzheimer's disease) as part of which they are investigating blood biomarkers for Alzheimer's disease.	N/A	12/07/2022 04/08/2022	N/A	It was agreed that these declarations would not prevent Dr Koychev from participating in discussions on this appraisal.
		Non-financial	Dr Koychev had a collaboration with Roche as part of which digital technologies were developed for the detection of cognitive impairment in ageing adults. This has now concluded.				
Professor David Meads	Committee Member	Indirect - financial	Professor Meads' employer, the University of Leeds, has received funding from Janssen and BMS for research in an unrelated area.	N/A	03/10/2022	N/A	It was agreed that his declaration would not prevent Professor Meads from participating in discussions on this appraisal.



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Alistair Greystoke	Clinical expert	Direct – financial & non-financial interests	Dr Alistair Greystoke declared the following interests:  • He has received consultancy and speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche and Takeda for treatments in NSCLC. (The underlined companies have agents under appraisal in this particular indication)  • He is a clinical lead for cancer for the NEY Genomic Laboratory Hub responsible for genomic testing in his region.  • He is a member of the Genomics Test Evaluation Working Group (Cancer)	N/A	24/11/2021 04/08/2022	N/A	It was agreed that these declarations would not prevent Dr Greystoke from providing expert advice to the committee.